Key Takeaways
- People with spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, appear to have a higher rate of obstructive sleep apnea than the general population.
- Both conditions share overlapping biological pathways — particularly intermittent oxygen loss, oxidative stress, and the same inflammatory signaling molecules — suggesting they may amplify each other.
- OSA-related oxygen drops at night may worsen inflammation, fatigue, and pain in people with spondyloarthritis, potentially increasing cardiovascular risk.
- Preliminary evidence suggests that treating OSA with CPAP therapy, or controlling SpA with biologic drugs, may improve outcomes for both conditions — though much more research is needed.
For many people living with spondyloarthritis — a family of inflammatory conditions that includes ankylosing spondylitis and psoriatic arthritis — poor sleep feels like an unavoidable companion to the disease. Pain wakes them up. Stiffness sets in by 3 a.m. Fatigue follows them into the morning regardless of how many hours they spent in bed. But a growing body of research is now pointing to a specific sleep disorder — obstructive sleep apnea (OSA) — as a potential hidden player in this cycle, and a new narrative review published in a peer-reviewed journal has attempted to map just how deep that connection runs.
The review draws together epidemiological data, mechanistic research, and clinical studies to build a picture of two chronic inflammatory conditions that may be far more intertwined than most clinicians currently appreciate.
People with ankylosing spondylitis and psoriatic arthritis show higher rates of obstructive sleep apnea than the general population — and OSA-related oxygen loss at night may be actively worsening the inflammation that drives their joint disease.
This emerging link suggests that untreated sleep apnea could be an overlooked factor in poor disease control for some spondyloarthritis patients.
What Spondyloarthritis and Sleep Apnea Have in Common at the Cellular Level
Spondyloarthritis (SpA) is an umbrella term for a group of related inflammatory conditions that primarily affect the spine and joints, though they can also involve the skin, gut, and eyes. The most well-known subtypes are ankylosing spondylitis, which causes inflammation and eventual fusion of spinal joints, and psoriatic arthritis, which occurs in some people with the skin condition psoriasis.
Obstructive sleep apnea, meanwhile, is a disorder in which the throat muscles intermittently relax and block the airway during sleep, causing repeated brief episodes of oxygen deprivation. It is strongly associated with obesity, cardiovascular disease, and metabolic problems — and it is far more common than many people realize.
On the surface, these two conditions seem unrelated. But the review authors identified a striking overlap in their underlying biology. Both involve elevated levels of TNF-alpha, a key driver of inflammatory joint damage in SpA. Both also engage the IL-17/IL-23 axis — the same inflammatory signaling pathway that several modern biologic drugs are designed to block in spondyloarthritis treatment. Additionally, both conditions are associated with oxidative stress (cellular damage from unstable oxygen molecules), dysfunction of the blood vessel lining, and disruption of the autonomic nervous system, which controls heart rate and other automatic body functions.
The repeated drops in blood oxygen that define OSA appear to activate many of the same inflammatory pathways that spondyloarthritis already has in overdrive. This creates a theoretical feedback loop: SpA drives systemic inflammation that may worsen sleep quality and airway instability, while OSA-related oxygen loss further amplifies inflammatory signaling that could worsen joint disease, fatigue, and pain.
Why People With SpA May Be Especially Prone to Developing Sleep Apnea
The link is not purely molecular — there are also straightforward structural and metabolic reasons why spondyloarthritis patients may face elevated OSA risk.
Why SpA Patients May Be More Vulnerable to Obstructive Sleep Apnea
| Risk Factor | How SpA Contributes |
|---|---|
| Spinal restriction | Fusion or stiffening of the cervical and thoracic spine can alter neck posture and compress the upper airway, reducing airflow during sleep. |
| Obesity and metabolic syndrome | Both are more common in SpA patients, and excess weight around the neck is a primary mechanical driver of airway collapse in OSA. |
| Chronic systemic inflammation | Persistent inflammation affects muscle tone and tissue throughout the body, potentially including upper airway muscles involved in keeping the throat open. |
| Altered sleep architecture | SpA-related pain and stiffness disrupt normal sleep cycles, reducing time in the deep sleep stages where the body regulates muscle tone most effectively. |
Available studies do confirm an increased prevalence of OSA among people with ankylosing spondylitis and psoriatic arthritis. However, the review is careful to note that this evidence base has significant limitations — studies have often involved small groups of patients, used different methods for diagnosing sleep apnea, and relied on cross-sectional designs that can identify associations but cannot determine which condition came first or whether one is truly causing the other.
Correcting a Common Assumption: Fatigue in SpA Isn't Always Just the Arthritis
One of the most clinically important takeaways from this review is a challenge to a widespread assumption in rheumatology: that fatigue and poor sleep in spondyloarthritis patients can be adequately explained by the disease itself.
Fatigue is one of the most commonly reported and most disabling symptoms in SpA. Clinicians have historically attributed it primarily to inflammatory disease activity or the psychological burden of living with a chronic condition. But if a meaningful proportion of SpA patients also have undiagnosed sleep apnea — which itself causes profound fatigue, cognitive fog, and mood disruption through nightly oxygen deprivation — then treating the underlying arthritis alone will never fully address the problem.
The review's authors suggest that OSA should be considered in the differential assessment of SpA patients who report persistent fatigue, especially those with obesity, metabolic syndrome, or cervical spine involvement — all of which compound airway risk. In this sense, what looks like undertreated arthritis may sometimes be a missed sleep disorder running in parallel.
Could Treating One Condition Help the Other?
Perhaps the most intriguing question raised by the review is whether interventions aimed at one condition might benefit the other. The short answer, based on current evidence, is: possibly — but we do not yet have the proof to say so definitively.
Continuous positive airway pressure (CPAP) therapy — the gold-standard treatment for OSA, which keeps the airway open through gentle air pressure delivered via a mask — has been shown in other inflammatory contexts to reduce certain inflammatory markers. The review notes preliminary evidence that CPAP may have favorable effects on inflammation and sleep outcomes in patients who have both OSA and inflammatory disease, though studies specifically in SpA populations remain scarce.
On the other side, biologic therapies used to treat SpA — particularly those targeting TNF-alpha or the IL-17/IL-23 axis — theoretically reduce the same inflammatory signals that OSA amplifies. Some limited evidence suggests these drugs may improve sleep-related outcomes as a secondary benefit, though this has not been formally studied as a primary endpoint in the SpA population.
What This Review Cannot Yet Tell Us
What This Means for People Living With Spondyloarthritis
While the science is still catching up, the practical message from this review is meaningful. If you have spondyloarthritis and struggle with persistent fatigue, unrefreshing sleep, daytime sleepiness, or your bed partner has noticed you snoring heavily or pausing your breathing at night, it is worth raising the possibility of sleep apnea with your doctor — even if you assume your symptoms are simply part of your arthritis.
Managing your weight, where possible, remains one of the most evidence-supported strategies for reducing OSA risk — and given that obesity also worsens SpA-related cardiovascular risk, this is doubly relevant. The review also underscores that both conditions carry substantial heart and metabolic risks independently, and their coexistence likely amplifies that burden further, making comprehensive cardiometabolic monitoring an important part of care for people dealing with both.
Questions Worth Raising at Your Next Appointment
If you have spondyloarthritis and have concerns about your sleep quality or fatigue, consider asking your rheumatologist or primary care doctor:
- Could my fatigue be partly explained by a sleep disorder like OSA, rather than my arthritis alone?
- Should I be screened for obstructive sleep apnea, and if so, what does that screening involve?
- If I do have OSA and spondyloarthritis together, how does that affect my cardiovascular risk and how should we be monitoring it?
- Could treating OSA with CPAP therapy potentially improve my joint disease symptoms or inflammatory markers?
Researchers are calling for prospective, longitudinal studies that follow SpA patients over time, incorporate objective sleep testing, measure inflammatory biomarkers, and track rheumatologic outcomes simultaneously. That kind of multidisciplinary data would help clarify not just whether these conditions are linked, but how — and whether treating one offers a real pathway to easing the other. Until that evidence exists, the case for at least screening high-risk SpA patients for sleep apnea appears to be strengthening.
The interconnection between obstructive sleep apnoea and spondyloarthritis: pathophysiology, clinical evidence, and future perspectives.
Medical Disclaimer: The information provided on ChronicRelief.org is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.